Oritavancin(LY-333328,Orbactiv)|DC Chemicals

Oritavancin(LY-333328,Orbactiv)|DC Chemicals
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.

Product Name: Oritavancin Diphosphate（LY333328, Orbactiv） |Catalog Number:  DC8343 | cas: 937-13-3 (Oritavancin diphosphate salt); 171099-57-3 (Oritavancin) | Other names: LY333328; LY-333328; LY 333328; Oritavancin; brand name: Orbactiv | Chemical name： | Molecule Formula: C86H103Cl3N10O34P2 | MW: 1989.1

Oritavancin, also known as LY333328 and Orbactiv, is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci. Oritavancin was more active than either metronidazole or vancomycin against strains of Clostridium difficile tested. Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium. The 4'-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria. It also acts by inhibition of transglycosylation and inhibition of transpeptidation

For research and scientific purpose only, not for human use.